2025 annual financial data
Foghorn Therapeutics 2025 Operating margin
Direct answer
Operating margin was -265.64%.
Operating income was -82,107,000 USD and net income was -74,283,000 USD.
Operating cash flow was -86,099,000 USD.
Get free Foghorn Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 30,909,000 USD
- Operating income
- -82,107,000 USD
- Net income
- -74,283,000 USD
- Operating cash flow
- -86,099,000 USD